Synopsis There is an ongoing unmet need for effective therapies for Crohn’s disease (CD). Treatments for Crohn’s disease continue to evolve from the traditional biologics to novel small molecules with targeted mechanisms directed towards pathways that are dysregulated in Crohn’s disease. There are multiple emerging mechanisms of action including JAK inhibition, Smad7 inhibition, and Sphingosine-1-phosphate (S1P) receptor modulators that are administered as oral medications, and small molecules represent the next generation of therapies for Crohn’s disease.
All Keywords
【저자키워드】 small molecule, JAK inhibitor, Crohn’s disease, filgotinib, Ozanimod, TGF-β, SMAD7, mongersen, sphingosine-1-phosphate receptor,
【저자키워드】 small molecule, JAK inhibitor, Crohn’s disease, filgotinib, Ozanimod, TGF-β, SMAD7, mongersen, sphingosine-1-phosphate receptor,